- Home
- TSI vs SGMT Comparison
TSI vs SGMT Comparison
Compare TSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- SGMT
- Stock Information
- Founded
- TSI 1987
- SGMT 2006
- Country
- TSI United States
- SGMT United States
- Employees
- TSI N/A
- SGMT N/A
- Industry
- TSI Investment Managers
- SGMT
- Sector
- TSI Finance
- SGMT
- Exchange
- TSI Nasdaq
- SGMT Nasdaq
- Market Cap
- TSI 234.6M
- SGMT 269.2M
- IPO Year
- TSI N/A
- SGMT 2023
- Fundamental
- Price
- TSI $4.88
- SGMT $7.68
- Analyst Decision
- TSI
- SGMT Strong Buy
- Analyst Count
- TSI 0
- SGMT 6
- Target Price
- TSI N/A
- SGMT $23.17
- AVG Volume (30 Days)
- TSI 106.8K
- SGMT 3.6M
- Earning Date
- TSI 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- TSI 7.46%
- SGMT N/A
- EPS Growth
- TSI N/A
- SGMT N/A
- EPS
- TSI N/A
- SGMT N/A
- Revenue
- TSI N/A
- SGMT N/A
- Revenue This Year
- TSI N/A
- SGMT N/A
- Revenue Next Year
- TSI N/A
- SGMT N/A
- P/E Ratio
- TSI N/A
- SGMT N/A
- Revenue Growth
- TSI N/A
- SGMT N/A
- 52 Week Low
- TSI $4.48
- SGMT $1.73
- 52 Week High
- TSI $4.87
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- TSI 59.90
- SGMT 66.04
- Support Level
- TSI $4.80
- SGMT $6.56
- Resistance Level
- TSI $4.97
- SGMT $10.43
- Average True Range (ATR)
- TSI 0.04
- SGMT 1.32
- MACD
- TSI 0.00
- SGMT 0.21
- Stochastic Oscillator
- TSI 84.21
- SGMT 70.03
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.